A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...

A new study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...

Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...

Scientists at Duke-NUS Medical School and the National University Health System (NUHS), together with an international team ...

No gene acts alone: interacting variants and protein partnerships can worsen, mask or even rescue disease risk, demanding ...

Duke-NUS and NUHS scientists uncover a complex web of genetic, age-related and microbial factors that increase the risk of ...

When Joanna Meadows adopted Theodore, he was just a shelter puppy. She told Newsweek she had no idea of the change that was ...

The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.

After hearing Immaneni Rama Rao, counsel for the petitioner, the court directed issuance of notices to all respondents ...

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

Among the most famous demonstrations of genetic mutations driving infection outcome is severe combined immunodeficiency (SCID ...